Quanterix (NASDAQ:QTRX – Get Free Report) is expected to be issuing its Q1 2025 quarterly earnings data before the market opens on Tuesday, May 6th. Analysts expect the company to announce earnings of ($0.69) per share and revenue of $28.27 million for the quarter. Quanterix has set its FY 2025 guidance at EPS.
Quanterix (NASDAQ:QTRX – Get Free Report) last posted its quarterly earnings results on Monday, March 17th. The company reported ($0.30) EPS for the quarter, missing analysts’ consensus estimates of ($0.27) by ($0.03). The company had revenue of $35.16 million during the quarter, compared to analyst estimates of $34.93 million. Quanterix had a negative return on equity of 11.74% and a negative net margin of 30.12%. On average, analysts expect Quanterix to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.
Quanterix Trading Down 1.7 %
NASDAQ:QTRX opened at $5.78 on Tuesday. The stock has a market capitalization of $224.20 million, a price-to-earnings ratio of -5.45 and a beta of 1.35. The firm has a fifty day simple moving average of $6.50 and a two-hundred day simple moving average of $9.48. Quanterix has a 12 month low of $4.67 and a 12 month high of $19.18.
Wall Street Analyst Weigh In
Check Out Our Latest Report on QTRX
About Quanterix
Quanterix Corporation, a life sciences company, engages in development and marketing of digital immunoassay platforms that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific regions. The company offers HD-X instrument, a protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection in an expanded range of applications.
Featured Articles
- Five stocks we like better than Quanterix
- What is a SEC Filing?
- Kroger: This Must-Own Staples Stock Thrives in Every Market
- Financial Services Stocks Investing
- Aerospace and Defense Stocks Take Flight After Strong Earnings
- Buy P&G Now, Before It Sets A New All-Time High
- Occidental’s Hidden Gem: How OxyChem Could Boost Profits
Receive News & Ratings for Quanterix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quanterix and related companies with MarketBeat.com's FREE daily email newsletter.